Related Experiment Video
Updated: Nov 18, 2025
Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform
Published on: November 30, 2016
Irritable bowel syndrome and basal serum tryptase: correlation between subtype, severity, and comorbidities. A pilot
Constanza Ciriza de Los Ríos1, Isabel Castel de Lucas2, Fernando Canga Rodríguez-Valcárcel3
1Gastroenterology, Hospital Clínico San Carlos. Instituto de Investigacion Sanitaria San Carlos (IdISSC), España.
Basal serum tryptase (BST) levels do not differ between irritable bowel syndrome (IBS) patients and healthy individuals. However, elevated BST was observed in IBS patients with extraintestinal comorbidities, correlating with increased bloating severity.
Area of Science:
- Gastroenterology
- Immunology
- Clinical Medicine
Background:
- Mast cell activation impacts gut function, contributing to visceral hypersensitivity and dysmotility in functional gastrointestinal disorders.
- Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder characterized by altered gut function.
Purpose of the Study:
- To compare basal serum tryptase (BST) levels between IBS patients and healthy controls.
- To investigate BST variations based on IBS subtypes, comorbidities, and their correlation with IBS severity and quality of life.
Main Methods:
- A prospective case-control study involving IBS patients diagnosed using Rome IV criteria.
- Measurements included basal serum tryptase (BST), IBS Severity Score (IBSSS), pain, bloating, flatulence, IBS Quality of Life (IBSQOL), and Patient Health Questionnaire (PHQ-9).
Main Results:
- No significant difference in BST was found between IBS patients (4.8 ± 2.6) and controls (4.7 ± 2.6).
- BST levels did not vary across IBS subtypes (IBS-D vs. IBS-C) or correlate with IBS severity.
- BST was significantly higher in IBS patients with extraintestinal comorbidities, who also reported more severe bloating.
Conclusions:
- Basal serum tryptase (BST) does not serve as a diagnostic marker to differentiate IBS patients from healthy controls.
- Elevated BST in IBS patients with extraintestinal comorbidities warrants further investigation, particularly concerning its association with bloating.
Related Concept Videos
01:30Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
01:17Irritable Bowel Syndrome I: Introduction
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
01:17Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
01:30Irritable Bowel Syndrome III: Medical and Nursing Management
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.